Navigation Links
Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
Date:7/24/2012

analgesia and pain therapy; the potential of NKTR-181 to be less attractive as a target of user abuse than standard opioid therapies; the potential of NKTR-181 to exhibit reduced CNS-related side effects associated with standard opioid therapies; our plan to commence a separate human abuse liability study for NKTR-181 as part of Phase 2 development for the compound; the value of our polymer conjugate technology platform; and the potential of certain of our other drug candidates and those of our collaboration partners. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, observations and assumptions regarding the potential of our business, drug candidates and our technology. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements.  Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) the statements regarding the therapeutic potential of NKTR-181 are based on preclinical data and data from completed Phase 1 clinical studies and future clinical studies may not confirm these potential therapeutic benefits; (ii) although we have conducted various experiments using laboratory and home-based chemistry techniques that have so far been unable to convert NKTR-181 into a rapid-acting, more abusable opioid, there is a risk that an alternative chemistry technique or process may be discovered in the future that would enable the conversion of NKTR-181 into a more abusable opioid; (iii) NKTR-181 is in the earlier stages of
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 7, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer, today announced that Selected Value Therapeutics ... an exclusive license to develop and commercialize EntreMed,s Phase ... of its territories.  EntreMed retains development and commercialization rights ...
... June 7, 2011 Topaz Pharmaceuticals Inc., a privately ... Food and Drug Administration (FDA) accepted for filing the ... topical cream as a treatment for head lice infestations ... represents the transition of the Company from the development ...
Cached Medicine Technology:Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 2Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 3Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 4Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 2Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 3
(Date:7/10/2014)... the clinical indicators most strongly associated with concussion is ... evidence-based guidelines for concussion diagnosis, prognosis, and treatment, according ... , official journal of the Congress ... Lippincott Williams & Wilkins , a part of ... on analysis of the best available research data, a ...
(Date:7/10/2014)... just as tempting as full-fat equivalents could be ... into how proteins can replace fats without affecting ... the Engineering and Physical Sciences Research Council (EPSRC), ... of Edinburgh has produced modified proteins that easily ... the behaviour of fats during food manufacture. The ...
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... found that fecal transplantation is effective and safe for ... is the result of a study led by Colleen ... Gastrointestinal Medicine at The Women,s Medicine Collaborative. The study ... of print in the American Journal of Gastroenterology ... diff , has increased to epidemic proportions over the ...
Breaking Medicine News(10 mins):Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2
... confirms that impotence is a risk factor for heart ... suffering from both cardiovascular disease and erectile dysfunction are ... and death, a new study finds. , Moreover, treatments ... so the German researchers concluded that erectile dysfunction is ...
... ... between the corporate and academic worlds in the medical device industry. , ... (PRWEB) March 15, 2010 -- The First Annual ... Hosted by the Biomedical Engineering Society @ San Jose State University, this event will take ...
... ... at Children,s Memorial Hospital may be able to identify infants at high risk ... 48 hours after birth. The medical device making this possible is called the Pea ... fast, non-invasive mechanism to measure newborn body fat. , ...
... Reno , Salt Lake City , and Denver in May are set to help employers improve hearing conservation efforts and prevent noise-induced hearing loss among their workers. , ... , ... ... ...
... The Greater San Antonio Chamber of Commerce and ... at a luncheon on March 31st who have made ... part of the 2010 Women,s Opportunity Week (WOW), Ford Motor Company ... McClendon ( Texas State Representative, District 120 ), ...
... NEW YORK , March 15 Expectant mothers ... pregnancy experience thanks to the new Prenatal Yoga for Partners ... organic baby and toddler food company. One of the only products ... and founder Shazi Visram and her husband, Joe ...
Cached Medicine News:Health News:Erectile Dysfunction Plus Heart Disease Raises Death Risk 2Health News:Erectile Dysfunction Plus Heart Disease Raises Death Risk 3Health News:First Annual Bay Area Biomedical Device Conference to be Held at San Jose State University 2Health News:First Annual Bay Area Biomedical Device Conference to be Held at San Jose State University 3Health News:Study to Identify Infants at High Risk for Developing Obesity 2Health News:Study to Identify Infants at High Risk for Developing Obesity 3Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 2Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 3Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 4Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 5Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 6Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 7Health News:San Antonio Chamber Honors Women Business, Community Leaders 2Health News:San Antonio Chamber Honors Women Business, Community Leaders 3Health News:San Antonio Chamber Honors Women Business, Community Leaders 4Health News:HAPPYBABY Unveils Partners Prenatal Instructional Yoga DVD 2Health News:HAPPYBABY Unveils Partners Prenatal Instructional Yoga DVD 3Health News:HAPPYBABY Unveils Partners Prenatal Instructional Yoga DVD 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: